Cargando…

Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyung, Sun Young, Kim, Dae Young, Yoon, Jin Young, Son, Eun Suk, Kim, Yu Jin, Park, Jeong Woong, Jeong, Sung Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879815/
https://www.ncbi.nlm.nih.gov/pubmed/29609658
http://dx.doi.org/10.1186/s40360-018-0204-7
_version_ 1783311056325574656
author Kyung, Sun Young
Kim, Dae Young
Yoon, Jin Young
Son, Eun Suk
Kim, Yu Jin
Park, Jeong Woong
Jeong, Sung Hwan
author_facet Kyung, Sun Young
Kim, Dae Young
Yoon, Jin Young
Son, Eun Suk
Kim, Yu Jin
Park, Jeong Woong
Jeong, Sung Hwan
author_sort Kyung, Sun Young
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. METHODS: In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. RESULTS: SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. CONCLUSIONS: SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-018-0204-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5879815
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58798152018-04-04 Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition Kyung, Sun Young Kim, Dae Young Yoon, Jin Young Son, Eun Suk Kim, Yu Jin Park, Jeong Woong Jeong, Sung Hwan BMC Pharmacol Toxicol Research Article BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease with no effective treatment. The epithelial-mesenchymal transition (EMT) is a critical stage during the development of fibrosis. To assess the effect of sulforaphane (SFN) on the EMT and fibrosis using an in vitro transforming growth factor (TGF)-β1-induced model and an in vivo bleomycin (BLM)-induced model. METHODS: In vitro studies, cell viability, and cytotoxicity were measured using a Cell Counting Kit-8. The functional TGF-β1-induced EMT and fibrosis were assessed using western blotting and a quantitative real-time polymerase chain reaction. The lungs were analyzed histopathologically in vivo using hematoxylin and eosin and Masson’s trichrome staining. The BLM-induced fibrosis was characterized by western blotting and immunohistochemical analyses for fibronectin, TGF-β1, E-cadherin (E-cad), and α-smooth muscle actin (SMA) in lung tissues. RESULTS: SFN reversed mesenchymal-like changes induced by TGF-β1 and restored cells to their epithelial-like morphology. The results confirmed that the expression of the epithelial marker, E-cadherin, increased after SFN treatment, while expression of the mesenchymal markers, N-cadherin, vimentin, and α-SMA decreased in A549 cells after SFN treatment. In addition, SFN inhibited TGF-β1-induced mRNA expression of the EMT-related transcription factors, Slug, Snail, and Twist. The SFN treatment attenuated TGF-β1-induced expression of fibrosis-related proteins, such as fibronection, collagen I, collagen IV, and α-SMA in MRC-5 cells. Furthermore, SFN reduced the TGF-β1-induced phosphorylation of SMAD2/3 protein in A549 cells and MRC-5 cells. BLM induced fibrosis in mouse lungs that was also attenuated by SFN treatment, and SFN treatment decreased BLM-induced fibronectin expression, TGF-β1 expression, and the levels of collagen I in the lungs of mice. CONCLUSIONS: SFN showed a significant anti-fibrotic effect in TGF-β-treated cell lines and BLM-induced fibrosis in mice. These findings showed that SFN has anti-fibrotic activity that may be considered in the treatment of IPF. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40360-018-0204-7) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-02 /pmc/articles/PMC5879815/ /pubmed/29609658 http://dx.doi.org/10.1186/s40360-018-0204-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kyung, Sun Young
Kim, Dae Young
Yoon, Jin Young
Son, Eun Suk
Kim, Yu Jin
Park, Jeong Woong
Jeong, Sung Hwan
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_full Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_fullStr Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_full_unstemmed Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_short Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
title_sort sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5879815/
https://www.ncbi.nlm.nih.gov/pubmed/29609658
http://dx.doi.org/10.1186/s40360-018-0204-7
work_keys_str_mv AT kyungsunyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT kimdaeyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT yoonjinyoung sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT soneunsuk sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT kimyujin sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT parkjeongwoong sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition
AT jeongsunghwan sulforaphaneattenuatespulmonaryfibrosisbyinhibitingtheepithelialmesenchymaltransition